Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Lumos Pharma Inc LUMO

Healthcare Biotechnology
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing its clinical program and focused on identifying, acquiring, developing, and commercializing products and new therapies for people with rare diseases. Its pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone (GH) secretagogue, also... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:LUMO)

Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings

GlobeNewswire April 18, 2024

Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042

GlobeNewswire March 20, 2024

Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update

GlobeNewswire March 7, 2024

Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024

GlobeNewswire February 26, 2024

Lumos Pharma to Participate in Oppenheimer's 34th Annual Healthcare Life Sciences Conference

GlobeNewswire February 5, 2024

Lumos Pharma Promotes Pisit "Duke" Pitukcheewanont, MD to Chief Medical Officer

GlobeNewswire January 4, 2024

Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency

GlobeNewswire November 21, 2023

Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November

GlobeNewswire November 20, 2023

Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates

GlobeNewswire November 7, 2023
View More News ››

Opinion & Analysis (NDAQ:LUMO)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:LUMO)

Lumos Pharma to Report Full Year 2023 Financial Results and

JUST IN: $LUMO Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024AUSTIN, Texas, Feb. 26...
whytestocks - February 26, 2024

Real stock price share value

7.5
Nibinator - November 8, 2023
View more Bullboard ››

Southern Silver Exploration Corp.

Southern Silver Exploration Corp.

Southern Silver Exploration Corp is a Canadian company engaged in the acquisition, exploration, and development of natural ...
View More »